Neoadjuvant chemotherapy using reduced-dose docetaxel followed by radical prostatectomy for patients with intermediate and high-risk prostate cancer: a single-center study

BACKGROUND - To assess safety, pathologic response rate, and long-term oncologic outcomes of radical prostatectomy (RP) after neoadjuvant chemotherapy using reduced-dose docetaxel without androgen-deprivation therapy in prostate cancer (PCa) patients of intermediate- and high-risk groups.

METHODS - Forty-four patients with PCa (PSA > 10 ng/ml, Gleason score 7 or more, or clinical stage cT2c or more) were included with a median follow-up of 11. 4 years after RP. One group (NCT/RP) received neoadjuvant treatment 3-weekly with docetaxel (36 mg/m(2) for up to six cycles, 21 patients), the other (control) group (RP, 23 patients) received RP only.

RESULTS - Toxicities were mild with grade 3 events not exceeding 10%. A statistically significant reduction of PSA > 50% post-chemotherapy was observed in 52. 4% cases. Cancer-specific survival (CSS) was 90% in the NCT/RP group and 60. 9% in the RP group (P = 0. 042). The biochemical recurrence-free survival was 68. 5% in the NCT/RP and 37. 7% in the RP groups; overall survival was 75. 5% and 54. 6%, respectively (both P > 0. 05).

CONCLUSIONS - The use of neoadjuvant chemotherapy before RP in a selected regimen and dose represents a safe strategy and results in benefits in CSS. Given the limitations of the study, this concept should be evaluated in large, prospective, controlled studies. Prostate. © 2016 Wiley Periodicals, Inc.

The Prostate. 2016 Feb 11 [Epub ahead of print]

Alexander Nosov, Sergey Reva, Sergey Petrov, Eldar Mamijev, Roman Novikov, Florian Imkamp, Yuri Tolkach, Vladimir Moiseenko

Department of Oncological Urology, Petrov N. N. Research Institute of Oncology, Saint-Petersburg, Russia. , Department of Oncological Urology, Petrov N. N. Research Institute of Oncology, Saint-Petersburg, Russia. , Department of Oncological Urology, Petrov N. N. Research Institute of Oncology, Saint-Petersburg, Russia. , Department of Oncological Urology, Petrov N. N. Research Institute of Oncology, Saint-Petersburg, Russia. , Department of Oncological Urology, Petrov N. N. Research Institute of Oncology, Saint-Petersburg, Russia. , Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany. , Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany. , Saint-Petersburg Oncological Center, Saint-Petersburg, Russia.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe